​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GILD Stock Forecast

Gilead Sciences (GILD) stock forecast, based on 58 Wall Street analysts, predicts a 12-month average price target of $154.20, with a high of $177.00 and a low of $105.00. This represents a 4.73% increase from the last price of $147.23.

$50 $80 $110 $140 $170 $200 High: $177 Avg: $154.2 Low: $105 Last Closed Price: $147.23

GILD Stock Rating

Gilead Sciences stock's rating consensus is Buy, based on 58 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 37 Buy (63.79%), 20 Hold (34.48%), 1 Sell (1.72%), and 0 Strong Sell (0.00%).

Buy
Total 58 1 20 37 Strong Sell Sell Hold Buy Strong Buy

GILD Price Target Upside V Benchmarks

TypeNameUpside
StockGilead Sciences4.73%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks-2.30%

Price Target Trends

1M3M12M
# Anlaysts152337
Avg Price Target$158.80$152.65$144.08
Last Closing Price$147.23$147.23$147.23
Upside/Downside7.86%3.68%-2.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 265176-129
Jan, 265168--29
Dec, 255168--29
Nov, 254168--28
Oct, 254168--28
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 11, 2026Louise ChenScotiabank$177.00$155.2913.98%20.22%
Feb 11, 2026Morgan Stanley$171.00$155.729.81%16.14%
Feb 11, 2026Truist Financial$162.00$155.873.93%10.03%
Feb 11, 2026Truist Financial$152.00$154.69-1.74%3.24%
Feb 11, 2026Oppenheimer$165.00$153.467.52%12.07%
Feb 11, 2026Cantor Fitzgerald$155.00$147.235.28%5.28%
Feb 11, 2026Joseph StringerNeedham$170.00$154.0910.33%15.47%
Feb 11, 2026Robert W. Baird$145.00$153.89-5.78%-1.51%
Feb 11, 2026Evan SeigermanBMO Capital$160.00$147.238.67%8.67%
Feb 11, 2026Mohit BansalWells Fargo$165.00$147.2312.07%12.07%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 11, 2026ScotiabankOutperformOutperformhold
Feb 11, 2026BernsteinOutperformOutperformhold
Feb 11, 2026Morgan StanleyOverweightOverweighthold
Feb 11, 2026Bank of America SecuritiesBuyBuyhold
Feb 11, 2026OppenheimerOutperformOutperformhold
Feb 11, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 11, 2026NeedhamBuyBuyhold
Feb 11, 2026BMO CapitalOutperformOutperformhold
Feb 11, 2026Wells FargoOverweightOverweighthold
Jan 29, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 $11 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.96$3.66$4.54$0.38----
Avg Forecast$8.20$7.10$6.75$4.38$7.59$7.95$8.47$9.07
High Forecast$8.53$7.42$7.05$4.72$8.42$9.84$10.05$9.61
Low Forecast$7.96$6.84$6.58$3.87$6.40$5.77$5.94$8.66
Surprise %-39.51%-48.45%-32.74%-91.32%----

Revenue Forecast

$26B $27B $29B $31B $32B $34B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$27.30B$27.28B$27.12B$28.75B----
Avg Forecast$26.67B$26.53B$27.10B$28.32B$28.49B$29.34B$30.74B$32.22B
High Forecast$27.48B$27.44B$27.28B$28.60B$29.85B$29.36B$30.85B$33.68B
Low Forecast$26.05B$25.78B$26.91B$28.10B$27.87B$29.31B$30.63B$31.10B
Surprise %2.38%2.84%0.06%1.54%----

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.22B$4.59B$5.67B$480.00M----
Avg Forecast$5.09B$3.23B$5.67B$5.40B$9.33B$7.55B$8.20B$11.41B
High Forecast$6.10B$3.88B$6.80B$5.94B$10.60B$12.37B$12.64B$12.09B
Low Forecast$4.07B$2.58B$4.53B$4.87B$8.06B$7.26B$7.47B$10.90B
Surprise %22.36%42.16%--91.12%----

GILD Forecast FAQ

Is Gilead Sciences stock a buy?

Gilead Sciences stock has a consensus rating of Buy, based on 58 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 37 Buy, 20 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Gilead Sciences is a favorable investment for most analysts.

What is Gilead Sciences's price target?

Gilead Sciences's price target, set by 58 Wall Street analysts, averages $154.2 over the next 12 months. The price target range spans from $105 at the low end to $177 at the high end, suggesting a potential 4.73% change from the previous closing price of $147.23.

How does Gilead Sciences stock forecast compare to its benchmarks?

Gilead Sciences's stock forecast shows a 4.73% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (-2.30%).

What is the breakdown of analyst ratings for Gilead Sciences over the past three months?

  • February 2026: 17.24% Strong Buy, 58.62% Buy, 20.69% Hold, 0% Sell, 3.45% Strong Sell.
  • January 2026: 17.24% Strong Buy, 55.17% Buy, 27.59% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 17.24% Strong Buy, 55.17% Buy, 27.59% Hold, 0% Sell, 0% Strong Sell.

What is Gilead Sciences’s EPS forecast?

Gilead Sciences's average annual EPS forecast for its fiscal year ending in December 2025 is $7.59, marking a 1897.37% increase from the reported $0.38 in 2024. Estimates for the following years are $7.95 in 2026, $8.47 in 2027, and $9.07 in 2028.

What is Gilead Sciences’s revenue forecast?

Gilead Sciences's average annual revenue forecast for its fiscal year ending in December 2025 is $28.49B, reflecting a -0.91% decrease from the reported $28.75B in 2024. The forecast for 2026 is $29.34B, followed by $30.74B for 2027, and $32.22B for 2028.

What is Gilead Sciences’s net income forecast?

Gilead Sciences's net income forecast for the fiscal year ending in December 2025 stands at $9.33B, representing an 1842.97% increase from the reported $480M in 2024. Projections indicate $7.55B in 2026, $8.2B in 2027, and $11.41B in 2028.